


On-Demand HIV PrEP for Men at High Risk for HIV

IPERGAY

On-Demand HIV PrEP for MSM at High Risk for HIV

IPERGAY: Study Design

- **Background:** Randomized, phase 3, double-blind, placebo-controlled trial conducted in France and Canada that investigated tenofovir DF-emtricitabine as on-demand preexposure prophylaxis for men who have sex with men
- **Inclusion Criteria** (400 enrolled)
 - 18 years of age or older and HIV seronegative
 - Men or TG women who have sex with men
 - Unprotected anal sex ≥ 2 partners in prior 6 months
 - Excluded if chronic HCV or HBsAg-positive
 - Excluded: CrCl < 60 mL/min, glycosuria, proteinuria
- **Treatment Arms**
 - Placebo: (on-demand schedule*)
 - Tenofovir DF-emtricitabine: (on-demand schedule*)




***On demand Schedule:** take 2-pill loading dose of TDF-FTC or placebo with food 2-24 hours before sex, followed by a 3rd pill 24 hours after the 1st pill and a 4th pill 48 hours after the first 2 pills. With multiple consecutive episodes of sex, take 1 pill per day until 48 hours after last sex.

On-Demand HIV PrEP for MSM at High Risk for HIV

IPEGAY: Design


IPEGAY On-Demand Dosing Schedule



On-Demand HIV PrEP for MSM at High Risk for HIV

IPERGAY: Design


IPERGAY On-Demand Dosing Schedule with Ongoing HIV Exposures



On-Demand HIV PrEP for MSM at High Risk for HIV

IPERGAY: Results

Number of HIV Infections




Due to high effectiveness of PrEP, participants unrandomized and all offered PrEP

On-Demand HIV PrEP for MSM at High Risk for HIV

IPERGAY: Results

HIV Acquisition Risk Reduction



Due to high effectiveness of PrEP, participants unrandomized and all offered PrEP

On-Demand HIV PrEP for MSM at High Risk for HIV

IPERGAY: Conclusions

Conclusions: “The use of tenofovir DF-emtricitabine before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal and renal adverse events.”

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](https://www.hrsa.gov). This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

